{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "G",
      "alt": "S",
      "position": "2019"
    },
    "variant_string_id": "LRRK2 G2019S"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "LRRK2 is a serine/threonine kinase involved in Parkinson's disease (PD) pathogenesis. The G2019S mutation in LRRK2 is associated with increased kinase activity, a key mechanism in PD.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links LRRK2 kinase activity to PD and defines the G2019S mutation as a driver of increased kinase activity, directly relevant to disease pathogenesis."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "The study used kinase activity assays, which are widely accepted in the field for evaluating LRRK2 function in PD.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are a standard method for studying LRRK2's role in PD, aligning with the disease mechanism defined in Step 1. This class of assay effectively models the disease pathogenesis."
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "extracted_paper_info": "The assay included wild-type and mutant controls, and experiments were performed in triplicate. Known pathogenic variants (e.g., G2019S) were used as positive controls.",
      "judgment": "Yes",
      "reasoning": "Basic controls (wild-type and mutant) and replicates (triplicate experiments) were used. Variant controls (pathogenic variants) were included, meeting Sub-step 3c criteria."
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "extracted_paper_info": "The study reported a 150% increase in kinase activity for G2019S compared to wild-type, with a p-value <0.001. OddsPath was calculated as >18.7.",
      "judgment": "Yes",
      "reasoning": "Statistical analyses (p-value, effect size) and OddsPath (>18.7) were explicitly reported, meeting Sub-step 4c criteria for PS3_very_strong."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_very_strong"
  },
  "overall_conclusion": "The G2019S variant in LRRK2 is strongly supported by kinase activity assays showing a 150% increase in activity (p < 0.001) and OddsPath >18.7, meeting ACMG criteria for PS3_very_strong."
}